HIGHLIGHTS
- who: Riccardo Bomben from the School University of di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy have published the article: Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study, in the Journal: (JOURNAL) of 12/09/2022
SUMMARY
At baseline, before ibrutinib treatment, the authors identified a total of 296 TP53 mutations in 126 patients (median mutations per patient: 1; range of mutations/patient: 1-11; Supplementry are independently associated with a shorter outcome in ibrutinib-treated patients, single-hit aberrations (a single TP53 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.